Novo Nordisk A/S (NVO)
| Market Cap | 292.03B |
| Revenue (ttm) | 43.92B |
| Net Income (ttm) | 15.16B |
| Shares Out | 4.44B |
| EPS (ttm) | 3.40 |
| PE Ratio | 19.81 |
| Forward PE | 16.32 |
| Dividend | $1.61 (2.39%) |
| Ex-Dividend Date | Mar 31, 2025 |
| Volume | 15,584,129 |
| Open | 64.09 |
| Previous Close | 65.77 |
| Day's Range | 64.04 - 67.74 |
| 52-Week Range | 57.00 - 148.15 |
| Beta | 0.21 |
| Analysts | Strong Buy |
| Price Target | 128.00 (+89.91%) |
| Earnings Date | May 7, 2025 |
About NVO
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrin... [Read more]
Financial Performance
In 2024, Novo Nordisk's revenue was 290.40 billion, an increase of 25.03% compared to the previous year's 232.26 billion. Earnings were 100.99 billion, an increase of 20.68%.
Financial numbers in DKK Financial StatementsAnalyst Forecast
According to 4 analysts, the average rating for NVO stock is "Strong Buy." The 12-month stock price forecast is $128.0, which is an increase of 89.91% from the latest price.
News
Dr. Scott Gottlieb: What to expect from President Trump's executive order to lower drug prices
Scott Gottlieb, former FDA commissioner, joins CNBC's 'Squawk on the Street' to discuss how the White House may plan to cut drug prices.
Trump Declares War On Pharma Drug Pricing, But The Stocks Aren't Tanking - Yet
President Trump has announced today he plans to reduce U.S. drug prices by 30-80% via an Executive Order, targeting Big Pharma's high costs and profits. U.S. drug prices are significantly higher (up t...
Novo Nordisk Stock Is Slumping Today. Here's Why.
Shares of the Ozempic-maker fell while the rest of the market rose,as it's facing a hit to revenue from different directions.
Novo Nordisk: Nothing Has Changed, Except That It's Cheaper Now
Despite Novo Nordisk's stock decline, the company's competitive position is strengthening, driven by strong sales growth in Wegovy, Ozempic, and rare diseases. Eli Lilly's oral weight-loss drug announ...
Novo Nordisk A/S: Once-weekly Sogroya® (somapacitan) is an efficacious and well-tolerated long-acting growth hormone in children with growth disorders: results from REAL8 phase 3 basket study presented at the joint Congress of ESPE and ESE
Bagsværd, Denmark, 12 May 2025 – Novo Nordisk today presented data from the phase 3 REAL8 basket study, which showed that once-weekly Sogroya® (somapacitan) was non-inferior to the once-daily growth h...
Eli Lilly's Zepbound outperforms Novo Nordisk's Wegovy for weight loss in trial
Eli Lilly said on Sunday its drug Zepbound was superior to Novo Nordisk's Wegovy across five weight-loss targets such as reducing waist circumference, citing data from a head-to-head trial.
Wellness companies eager to avoid WeightWatchers' fate embrace weight-loss drugs
Health and wellness companies are embracing weight-loss drugs and building offerings around them in an effort to avoid the fate of WeightWatchers, which declared bankruptcy this week, citing vastly in...
Pharma Worries Shift to Prices From Trade. Trump's Next Plan Could Sink Stocks.
The president says big news about drug pricing is coming next week.
Novo Nordisk: It's Not Been This Cheap For Many Years
Novo Nordisk's stock has plummeted over 60%, while also arguably losing market share to Eli Lilly. Despite setbacks, Novo is actively enhancing market access for Wegovy and partnering with CVS and tel...
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
Bagsværd, Denmark, 9 May 2025 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company's board members, executives and their associated persons i...
Pressure is still on the pharma sector, says Mizuho's Jared Holz
Jared Holz, Mizuho, joins 'Fast Money' to talk headwinds to the pharma sector.
Novo Nordisk posts strong Q1 as weight-loss revolution claims another victim: WeightWatchers
One day after WeightWatchers said that it would file for bankruptcy, weight-loss drug giant Novo Nordisk's outlook is brightening.
GLP-1 competition heats up: Novo Nordisk CEO talks Wegovy, CVS deal, earnings
Pharmaceutical company Novo Nordisk (NVO) came out swinging Wednesday morning as the stock initially jumped on its first quarter earnings beat ($0.99 per share vs. estimates of $0.94).
Trump's trade war and inflation, Novo Nordisk CEO talks earnings
Catalyst anchor Madison Mills breaks down the market moves for May 7, 2025. First, all eyes are on the Federal Reserve.
Novo Nordisk A/S (NVO) Q1 2025 Earnings Call Transcript
Novo Nordisk A/S (NVO) Q1 2025 Results Conference Call May 7, 2025 7:00 AM ET Company Participants Jacob Rode - Head of Investor Relations Lars Jorgensen - President and Chief Executive Officer David ...
Novo Nordisk Q1 Earnings Review: Forget Revenue Miss, Buy Semaglutide Hype
Novo Nordisk A/S announced its Q1 earnings today, blaming a slight revenue miss on sales of compounded semaglutide. Q1 2025 earnings showed revenue of ~$11.9bn, operating profit of $5.9bn, with dilute...
SMCI Miss "Across the Board," NVO Wegovy Sales Up 85%, ANET Down on Beat
Diane King Hall discusses the biggest earnings movers this morning, including Novo Nordisk (NVO), which saw a 85% year-over-year increase in Wegovy sales but still trimmed guidance. Supermicro (SMCI) ...
Healthy Returns: Novo Nordisk's Wegovy deal with CVS won't derail Eli Lilly's obesity market dominance
Eli Lilly won't lose its grip on the weight loss market despite recent investor concerns. Meanwhile, Zocdoc releases an AI-powered scheduling assistant.
It's going to be 'put up or shut up' for Novo Nordisk's Wegovy this summer: Barclays' Emily Field
Emily Field, Barclacys head of European pharmaceuticals equity research, joins 'Squawk Box' to discuss Novo Nordisk's quarterly earnings results, impact of copycat compounded drugs on Wegovy sales, st...
Novo Nordisk Q1 2025: One Of The Best Deals You Can Get Right Now
Q1 2025 results show a 19% sales increase, 20% operating income growth, and 14% net profit rise, defying the 55% stock drop. Novo Nordisk's profitability and growth in emerging markets, coupled with a...
Novo Nordisk Stock Jumps Despite Full-Year Outlook Cut
U.S.-listed shares of Novo Nordisk (NVO) are jumping in premarket trading Wednesday even as the Danish pharmaceutical giant lowered its full-year outlook.
Novo Nordisk's CFO sceptical Trump executive order on drug manufacturing can cut timelines
Obesity drugmaker Novo Nordisk's CFO said on Wednesday he was sceptical that U.S. President Donald Trump's executive order to reduce the time it takes to approve pharmaceutical plants in the country w...
Novo Nordisk CEO says 'compounders took a part of our business away'
Novo Nordisk CEO Lars Fruergaard Jørgensen weighs in on the impact of compounded drugs on first-quarter Wegovy sales while forecasting a rebound later this year.
Drugmaker Novo Nordisk drops gender representation requirements in the US
Obesity drugmaker Novo Nordisk said on Wednesday it would drop gender representation requirements for its U.S. business following executive orders by President Donald Trump to stop diversity, equity a...
Novo Nordisk shares are rising after the company cut its outlook. It's been that kind of year.
Novo Nordisk is managing the unusual feat of seeing its stock price rise after reducing its earnings outlook.